Novo Nordisk's stock rose 24.9% in 30 days, underpinned by strong Q1 2026 earnings and investor confidence in AI-driven pipelines.1 The Danish pharma giant is now repositioning its portfolio: it is exiting its internal cell therapy unit and licensing its Parkinson's program to Cellular Intelligence, an AI-native cell therapy developer.1
The move signals a strategic shift — Novo Nordisk is choosing to deploy capital toward GLP-1 dominance while outsourcing early-stage cell therapy risk to AI-native partners. Cellular Intelligence's machine-learning approach to cell programming is central to that bet.
Across the Channel, French biotech Owkin is pressing its own advantage. Its OwkinZero platform targets AI-accelerated drug discovery, positioning the company as a European alternative to US-dominated players.1 Owkin joins a widening field of purpose-built AI drug discovery platforms — including Basecamp Research's EDEN and Boltz Lab — that are maturing beyond proof-of-concept.
The infrastructure layer consolidating beneath this competition is NVIDIA's BioNeMo platform. BioNeMo is now a shared backbone for partnerships with Eli Lilly and Thermo Fisher, embedding NVIDIA into the operating layer of pharma R&D.1 Lab digitisation is accelerating in parallel: Tetrascience and Thermo Fisher are building connected laboratory ecosystems that feed AI models with structured experimental data.
Regulatory signals are reinforcing the trend. FDA Fast Track designations for AI-assisted drug programs are reducing development timelines, giving pharma companies a concrete return on AI investment.1
For European players, the competitive pressure is structural. US platforms hold infrastructure advantages through NVIDIA partnerships and capital scale. Novo Nordisk's market validation and Owkin's platform ambition represent the two dominant European responses: integrate AI into established blockbuster pipelines, or build AI-first discovery infrastructure from the ground up.
Novo Nordisk's Q1 2026 results confirm that the first path generates near-term investor returns. Whether Owkin's platform approach can compete at scale — against both US peers and a reinvigorated Novo Nordisk — is the defining European biotech question of 2026.
